Statement by the African Union Commission Chairperson, HE Dr. Nkosazana Dlamini Zuma to the High level Meeting on Ebola Response

African Union [to 27 September 2014]
http://www.au.int/en/

Statement by the African Union Commission Chairperson, HE Dr. Nkosazana Dlamini Zuma to the High level Meeting on Ebola Response
UNGA, New York. 25 September 2014
Excerpt
…The current Ebola outbreak in parts of West Africa is unprecedented, both in terms of the region where it is occurring and the number of infections and deaths. Its occurrence in countries that have just emerged from conflicts and are still rebuilding their public health systems, as well as public trust and social cohesion, makes this a huge burden. It has a severe impact on health workers and women, who are at the frontline of the disease in these countries. It also adversely affects children, who are often left orphaned, with no families to take care of them.

Our coordinated and urgent responses to the crisis is therefore necessary: to provide the three countries with financial assistance, with equipment, protective clothing, mobile laboratories and other facilities, to be able to track and contain the disease, and to provide treatment to the sick in a secure environment. Most important, as a result of the severe impact on health workers in these countries, they require health personnel (doctors, technicians, clinicians, nurses) that can help with the immediate and urgent interventions.

Many organizations have shown their solidarity by being in the frontline of efforts in these countries, and we must here single out the medical professionals and health workers especially from Médecins Sans Frontières, the Red Cross, Samaritan’s Purse, as well as the US Centre for Disease Control. The African Union Ebola Outbreak in West Africa (ASEOWA), has started deploying the first team of medical and other volunteer personnel from various African countries to Liberia. This includes medical specialists from countries such as Uganda and the DRC that have dealt with Ebola before. We shall be sending further teams to Sierra leone and Guine, but it is yet a drop in the oceans, we need hundreds more volunteers.

Secondly, we have to ensure that countries in the neighbourhood and other regions have systems in place to prevent and trace infection. The ECOWAS and African Ministers of Health, working with the World Health Organisations, since their first meetings in April this year, have already begun to coordinate national and regional efforts in this regard.

Thirdly, the disease in its current manifestations also place economic burdens on the countries concerned, ranging from fiscal strains with money having to be diverted from other causes to fight the disease, restrictions on informal and cross-border trade, as well as on agriculture. Our comprehensive measures therefore have to also look at this economic dimension and we thank the World Bank and the African Development Bank for their efforts in this regard, but we should all do more in this regard.
The recent Emergency session of the African Union Executive Council n

ted that we should avoid compounding the burden on the affected states, by taking measures whose impact may lead to worse consequences than the disease itself. It was in this context that the Emergency session called on Member states to lift all travel bans on flights and passengers from the affected countries, and to cooperate to put in place measures at borders to ensure screening. We thank those countries who have already lifted the travel ban, and urged those who have not done so to recommence flights to these countries…

IMF Executive Board Approves US$130 Million in Immediate Assistance to Guinea, Liberia, and Sierra Leone in Response to the Ebola Outbreak

IMF [to 27 September 2014]
http://www.imf.org/external/index.htm

IMF Executive Board Approves US$130 Million in Immediate Assistance to Guinea, Liberia, and Sierra Leone in Response to the Ebola Outbreak
Press Release No. 14/441
September 26, 2014
The Executive Board of the International Monetary Fund (IMF) today approved—in an expedited decision supported by a joint statement of all Directors—emergency financial assistance to Guinea, Liberia, and Sierra Leone totaling US$130 million to help respond to the Ebola outbreak. The IMF financing will be made available to the three countries immediately, in the amounts of US$41 million for Guinea, US$49 million for Liberia and US$40 million for Sierra Leone. This emergency financing comes in addition to the assistance provided under existing programs for these countries. It will help cover part of the immediate balance of payments and fiscal needs currently estimated at about US$100 million for each country.

“The Ebola outbreak in Guinea, Liberia, and Sierra Leone has already cost too many lives,” said IMF Managing Director Christine Lagarde. “This humanitarian crisis could also have deep economic consequences. The governments of Guinea, Liberia and Sierra Leone requested IMF support to enhance their efforts to contain this unprecedented epidemic that is disproportionately affecting the most vulnerable in their populations. The IMF is working hard with the authorities of the affected countries and their development partners to ensure that the outbreak is quickly brought under control and to assist the economic rebuilding effort that must follow.”

The Ebola Outbreak affecting the three countries has created a significant social and humanitarian crisis, and has so far proven difficult to contain despite efforts by the respective governments and their development partners. It is also having an acute macroeconomic and social impact on the three already-fragile countries. The crisis is still unfolding, but preliminary IMF estimates indicate that growth could decline by at least 3-3½ percent in Liberia and Sierra Leone and by about 1½ percent in Guinea in 2014. Inflationary pressures have flared up in the affected countries, and significant fiscal financing needs have emerged as the outbreak has caused sharp declines in tax revenues and Ebola-related spending had to be increased substantially. Additional and sizeable budget support from bilateral and multilateral development partners is urgently needed to avoid painful domestic adjustment measures and help eradicate the disease…

World Bank [to 27 September 2014] [Ebola actions]

World Bank [to 27 September 2014]
http://www.worldbank.org/en/news/all

Speech by World Bank Group President Jim Yong Kim at the High-Level Meeting on Response to the Ebola Virus Disease Outbreak
September 25, 2014
Thank you very much, Deputy Secretary General, Excellencies, President Condé of Guinea and, online, President Johnson Sirleaf from Liberia, President Koroma of Sierra Leone, ladies and gentlemen.I spoke to all three of the leaders yesterday, I spoke to friends and colleagues who just returned from the region, and I first want to thank all of the three leaders for their courage and determination in the face of this epidemic. But I just want to also give you a bit of my sense, as an infectious disease doctor, of what I see as the seriousness of this epidemic.I have spent most of my adult life fighting very, very complicated, difficult epidemics, like drug-resistant tuberculosis in some of the poorest countries in the world. I have been involved in the treatment of HIV, again in some of the poorest countries in the world. But I have never seen anything close to the challenge that we’re facing.The speed, complexity and the magnitude of the response that is required is unlike anything we’ve…

WBG Approves US$750,000 to prevent Ebola in Guinea-Bissau
DAKAR, September 25, 2014 – The World Bank has approved financing to the Government of Guinea–Bissau for a health contingency plan that would help prevent the spread of the Ebola virus to the country. Although it has no recorded cases of Ebola to date, the new funding of US$750,000 responds to an urgent request from the government for financing of an Ebola action plan prepared by the Ministry of Public Health, in collaboration with the World Health Organization (WHO).According to Philippe Auffret, World Bank Task Team Leader of the project, “this support is to finance an information campaign through the Government’s existing community-driven Project and finance health measures including training of health staff on Ebola…

World Bank Group to Nearly Double Funding in Ebola Crisis to $400 Million
September 25, 2014
Significant new assistance planned for hardest-hit countriesWASHINGTON, September 25, 2014—Following alarming evidence of the spread of the Ebola epidemic in West Africa, the World Bank Group today announced that it will nearly double its financing to $400 million to help the worst-affected countries address the emergency and build stronger health systems for the years aheadThis represents $170 million in new funding. With today’s announcement, the Bank will put $230 million toward the emergency response and $170 million for medium- and long-term projects. The new resources – which the World Bank’s Board of Executive Directors will consider in the coming weeks – will be targeted at rapidly increasing the health care workforce and purchasing needed supplies in order to bring care and treatment to all parts of the affected countries. The funding also is aimed at building a stronger health care system because it will aim to train cadres of health workers to bolster care at a community level…

BRAC commits to massive scale-up in girls’ education

BRAC [to 27 September 2014]

BRAC commits to massive scale-up in girls’ education
Global anti-poverty leader pledges to invest at least $280 million to reach 2.7 million additional girls and train 75,000 teachers by 2019
[Undated announcement]
BRAC, already a global leader in providing opportunity for the world’s poor, has boosted its commitment to girls’ education in low-income countries with a five-year pledge to reach 2.7 million additional girls through primary and pre-primary schools, teacher training, adolescent empowerment programmes, scholarships and other programmes.

These commitments make BRAC a leading partner in CHARGE, the Collaborative for Harnessing Ambition and Resources for Girls Education, a global collaborative of more than 30 partners working to advance the “second generation” of global girls’ education. The initiative was announced today by Hillary Rodham Clinton, former US secretary of state; Chelsea Clinton, Clinton Foundation vice-chair; and Julia Gillard, former prime minister of Australia, at the 10th Clinton Global Initiative Annual Meeting in New York.

“We have always used an approach to development that puts power in the hands of the poor themselves, especially women and girls,” says Sir Fazle Hasan Abed, the founder and chairperson of BRAC, who joined other leaders at Clinton Global Initiative today to launch the initiative. “Educated girls turn into empowered women, and as we have seen in my native Bangladesh and elsewhere, the empowerment of women leads to massive improvements in quality of life for everyone, especially the poor.”

BRAC is already the world’s largest private, secular education provider, with 1.3 million boys and girls now enrolled in 43,500 primary and pre-primary schools and 311,000 participants in its adolescent development programmes. Formerly Bangladesh Rural Advancement Committee, BRAC is now active in a dozen countries, serving the poor through the empowerment of women and girls with tools such as microfinance, education, healthcare and a full-fledged university, BRAC University in Dhaka.

This commitment significantly expands BRAC’s existing education programmes by reaching an additional 1.3 million girls directly in BRAC schools, roughly 636,000 additional girls through teacher training in government schools, and 714,000 more through various other programmes, including adolescent empowerment, gender harassment awareness, mentorship programmes, and scholarships.

BRAC estimates the investments needed to fulfill these commitments will be more than $280 million, over half of which has already been raised from partnerships with AusAid, UK Aid and The MasterCard Foundation…

Global Fund Watch [to 27 September 2014]

Global Fund Watch [to 27 September 2014]
http://www.theglobalfund.org/en/mediacenter/announcements/

:: Ecobank Expands Partnership with Global Fund
23 September 2014
JUBA, South Sudan – Ecobank Group and the Global Fund to Fight AIDS, Tuberculosis and Malaria are expanding a partnership to include South Sudan after collaborating since 2011 on capacity-building programs for Global Fund implementers in Cote d’Ivoire and Nigeria.
Building on this successful experience, the two parties announced in Juba they have concluded a three to five years’ agreement to formalize Ecobank’s support for the Global Fund’s work and programs in a number of countries in Africa, including South Sudan.
The Global Fund program in South Sudan is being implemented through the United Nations Development Programme (UNDP) and Population Services International (PSI)…

:: Landmark HIV Diagnostic Access Program Will Save $150m
26 September 2014
Roche has announced a major Global Access Program to sharply lower the price of HIV viral load tests in low- and middle-income countries. This new initiative creates a ceiling price of US$9.40 per test, and will reduce Roche’s average price by more than 40% in low- and middle-income countries. When fully implemented, the Global Access Program is projected to save more than US$150 million in costs over the next five years.
By increasing access to viral load testing, this new deal will dramatically improve the quality of HIV treatment services and strengthen capacity to achieve the global goal of ensuring that 90% of all people receiving antiretroviral therapy achieve viral suppression. The high price of viral load testing – is an important reason why less than one in four people on antiretroviral therapy currently have access to viral load testing…

The Sphere Project [to 27 September 2014]

The Sphere Project [to 27 September 2014]
http://www.sphereproject.org/news/

Christine Knudsen appointed Sphere Project Director
26 September 2014
The Sphere Board has appointed Christine Knudsen as Sphere Project Director. Knudsen will take up her new position on 1 November 2014. Knudsen brings 17 years of experience…

Cast your vote in the final consultation on the Core Humanitarian Standard
24 September 2014
The third version of the Core Humanitarian Standard (CHS) on Quality and Accountability will be available for consultation from 29 September to 17 October.

Hewlett Foundation Announces $5 Million in Emergency Funding for Ebola Response

William and Flora Hewlett Foundation
http://www.hewlett.org/newsroom/search

The William and Flora Hewlett Foundation Announces $5 Million in Emergency Funding for Ebola Response
Sep 25, 2014
MENLO PARK, Calif.– The William and Flora Hewlett Foundation today announced it has committed $5 million in grant funding to help contain the West African outbreak of the Ebola virus…
…Recent days have seen several large-scale commitments of funding to halt the spread of the virus, and Hewlett Foundation staff consulted with experts in government, international development agencies, and nonprofit organizations working in the region to decide where the Foundation’s funds could do the most good…

…The Hewlett Foundation’s grants will support organizations working on high-priority public health measures, including the use of mass media for prevention messages; operation of Ebola treatment centers; and community-based outreach. Organizations that will receive grants as part of the Ebola response fund include the CDC Foundation, the UN Foundation, Humanitarian OpenStreetMap Team (HOT), International Medical Corps, Population Services International, the GlobalGiving Foundation, and Capital for Good.

Increasing Childhood Influenza Vaccination

American Journal of Preventive Medicine
Volume 47, Issue 4, p375-530, e7-e10 October 2014
http://www.ajpmonline.org/current

Increasing Childhood Influenza Vaccination
A Cluster Randomized Trial
Mary Patricia Nowalk, PhD, RD, Chyongchiou Jeng Lin, PhD, Kristin Hannibal, MD, Evelyn C. Reis, MD, Gregory Gallik, DO, Krissy K. Moehling, MPH, Hsin-Hui Huang, MD, MPH, Norma J. Allred, PhD, David H. Wolfson, MD, Richard K. Zimmerman, MD, MPH, MA
Abstract
Background
Since the 2008 inception of universal childhood influenza vaccination, national rates have risen more dramatically among younger children than older children and reported rates across racial/ethnic groups are inconsistent. Interventions may be needed to address age and racial disparities to achieve the recommended childhood influenza vaccination target of 70%.
Purpose
To evaluate an intervention to increase childhood influenza vaccination across age and racial groups.
Methods
In 2011–2012, a total of 20 primary care practices treating children were randomly assigned to the intervention and control arms of a cluster randomized controlled trial to increase childhood influenza vaccination uptake using a toolkit and other strategies including early delivery of donated vaccine, in-service staff meetings, and publicity.
Results
The average vaccination differences from pre-intervention to the intervention year were significantly larger in the intervention arm (n=10 practices) than the control arm (n=10 practices); for children aged 9–18 years (11.1 pct pts intervention vs 4.3 pct pts control, p<0.05); for non-white children (16.7 pct pts intervention vs 4.6 pct pts control, p<0.001); and overall (9.9 pct pts intervention vs 4.2 pct pts control, p<0.01). In multi-level modeling that accounted for person- and practice-level variables and the interactions among age, race, and intervention, the likelihood of vaccination increased with younger age group (6–23 months); white race; commercial insurance; the practice’s pre-intervention vaccination rate; and being in the intervention arm. Estimates of the interaction terms indicated that the intervention increased the likelihood of vaccination for non-white children in all age groups and white children aged 9–18 years.
Conclusions
A multi-strategy intervention that includes a practice improvement toolkit can significantly improve influenza vaccination uptake across age and racial groups without targeting specific groups, especially in practices with large percentages of minority children.

Integrating Health Into Disaster Risk Reduction Strategies: Key Considerations for Success

American Journal of Public Health
Volume 104, Issue 10 (October 2014)
http://ajph.aphapublications.org/toc/ajph/current

Integrating Health Into Disaster Risk Reduction Strategies: Key Considerations for Success
Osman Dar, Emmeline J. Buckley, Sakib Rokadiya, Qudsia Huda, Jonathan Abrahams
American Journal of Public Health: October 2014, Vol. 104, No. 10: 1811–1816.
Abstract
The human and financial costs of disasters are vast. In 2011, disasters were estimated to have cost $378 billion worldwide; disasters have affected 64% of the world’s population since 1992. Consequently, disaster risk reduction strategies have become increasingly prominent on national and international policy agendas. However, the function of health in disaster risk reduction strategies often has been restricted to emergency response.
To mitigate the effect of disasters on social and health development goals (such as risk reduction Millennium Development Goals) and increase resilience among at-risk populations, disaster strategies should assign the health sector a more all-encompassing, proactive role.
We discuss proposed methods and concepts for mainstreaming health in disaster risk reduction and consider barriers faced by the health sector in this field.

A framework for community ownership of a text messaging programme to improve adherence to antiretroviral therapy and client-provider communication: a mixed methods study

BMC Health Services Research
(Accessed 27 September 2014)
http://www.biomedcentral.com/bmchealthservres/content

Research article
A framework for community ownership of a text messaging programme to improve adherence to antiretroviral therapy and client-provider communication: a mixed methods study
Lawrence Mbuagbaw, Renee-Cecile Bonono-Momnougui, Lehana Thabane, Charles Kouanfack, Marek Smieja, Pierre Ongolo-Zogo BMC Health Services Research 2014, 14:441 (26 September 2014)
Abstract (provisional)
Background
Mobile phone text messaging has been shown to improve adherence to antiretroviral therapy and to improve communication between patients and health care workers. It is unclear which strategies are most appropriate for scaling up text messaging programmes. We sought to investigate community acceptability and readiness for ownership (community members designing, sending and receiving text messages) of a text message programme among a community of clients living with human immunodeficiency virus (HIV) in Yaounde, Cameroon and to develop a framework for implementation.
Methods
We used the mixed-methods sequential exploratory design. In the qualitative phase we conducted 10 focus group discussions (57 participants) to elicit themes related to acceptability and readiness. In the quantitative phase we explored the generalizability of these themes in a survey of 420 clients. Qualitative and quantitative data were merged to generate meta-inferences.
Results
Both qualitative and quantitative strands showed high levels of acceptability and readiness despite low rates of participation in other community led projects. In the qualitative strand, compared to the quantitative strand, more potential service users were willing to pay for a text messaging service, preferred participation of health personnel in managing the project and preferred that the project be based in the hospital rather than in the community. Some of the limitations identified to implementing a community-owned project were lack of management skills in the community, financial, technical and literacy challenges. Participants who were willing to pay were more likely to find the project acceptable and expressed positive feelings about community readiness to own a text messaging project.
Conclusion
Community ownership of a text messaging programme is acceptable to the community of clients at the Yaounde Central Hospital. Our framework for implementation includes components for community members who take on roles as services users (demonstrating clear benefits, allowing a trial period and ensuring high levels of confidentiality) or service providers (training in project management and securing sustainable funding). Such a project can be evaluated using participation rate, clinical outcomes, satisfaction with the service, cost and feedback from users.

BMJ Editorial: Ebola in an unprepared Africa

British Medical Journal
27 September 2014(vol 349, issue 7976)
http://www.bmj.com/content/349/7976

Editorials
Ebola in an unprepared Africa
BMJ 2014; 349 doi: http://dx.doi.org/10.1136/bmj.g5597 (Published 15 September 2014) Cite this as: BMJ 2014;349:g5597
Oyewale Tomori, professor of virology
Author affiliations
Governments of affected countries need help but must take the lead in protecting their citizens

The 2 year old boy who died in December 2013 in Gueckedou, Guinea, is considered the index case of the current outbreak of Ebola virus disease caused by the Zaire species.1 Up until 2014, the disease was limited to rural areas of east and central Africa,2 but it has now spread to Liberia, Sierra Leone, Nigeria, and Senegal. By 6 September 2014, 4293 cases and 2296 deaths had been reported in the current outbreak,3 which, by the time the outbreak is controlled, is likely to surpass the total number of cases and deaths reported for all 22 Ebola outbreaks that have occurred in Africa since 1976, when the disease was first described.3 The World Health Organization has declared the current outbreak an “out of control” public health emergency of international concern.4

One of the reasons for the unprecedented epidemic is that Ebola is spreading in three countries ranked among the poorest in the world. The 2014 Human Development Index ranks Liberia, Guinea, and Sierra Leone at 175, 179, and 183, respectively, of 187 countries.5 Whereas Liberia and Sierra Leone are recovering from civil wars, Guinea has been affected by chronic underdevelopment allowed and ignored by successive governments. Around a fifth of the citizens of these three countries live in extreme poverty.6 Health facilities and services are wholly inadequate. For example, Liberia has 0.1 physicians, 1.7 nurses and midwives, and eight hospital beds for every 10 000 people.7

To date, more than 240 healthcare workers have developed Ebola virus disease in Guinea, Liberia, Nigeria, and Sierra Leone and more than 120 have died.8 In addition to fragile health systems, several other contributory factors have compromised our ability to mount an adequate response. Poor disease surveillance and response systems make early detection and control of outbreaks inefficient and unreliable. In addition, unmanned borders artificially separate people of the same ethnic origin and cultural background into different nationalities, resulting in a high level of movement across borders and uncontrolled cross border movement of infected people. The death of healthcare workers has led to a shortage of workers to care for patients with other diseases and hospital closures. Ignorance and misconceptions about the virus’s mode of transmission and customary burial ceremonies complicate the situation further.

Governments of affected countries were initially in denial over the occurrence of the disease. Subsequently, they relinquished responsibility for the care of infected patients to overworked international non-governmental organisations and issued incoherent directives, such as the closure of markets and borders. The Ebola outbreak has now become so serious that health infrastructure is beginning to collapse and hospitals are closing. Without effective medical care patients are dying not only of Ebola but of malaria, diarrhoea, and other conditions. The medical charity Médecins Sans Frontières recently commented that it will take at least another six months to bring the epidemic under control.9 The organisation’s president and general director have described the international response to its repeated calls “for more hands-on assistance to control the epidemic and to provide the best possible care to patients” as “slow, derisory, [and] irresponsible.”10

What must be done to stop transmission and control the epidemic?
The current epidemic is beyond the capacity and capability of the affected nations. Ending the Ebola outbreak in west Africa and preventing a global calamity requires commitment and collaboration of national and international governments and agencies. The affected countries need urgent help with strengthening and sustaining basic infection control procedures to stop transmission of disease. These include daily tracking of people who come into contact with sick or dead people and monitoring them for the 21 day incubation period; documentation of historical and ongoing chains of virus transmission to ensure that accurate numbers of cases and deaths are recorded and to provide information on transmission of disease; identification of deaths in the community and ensuring safe burial practices; and improving specimen referral and strengthening laboratory diagnostic capacity. Healthcare workers must be educated on these practices to substantially reduce healthcare associated transmission.

National governments urgently need to communicate with the population to restore confidence and to ensure acceptance of healthcare services. They need to educate people on the community’s role in control of the disease and to enumerate government action and efforts in controlling the disease. They must show leadership and assume responsibility for the welfare of their citizens by prioritising the provision of adequate funds for procuring personal protective equipment and hospital supplies and paying salaries to healthcare workers. National professional groups—including medical associations, veterinarians, scientists, the media and non-governmental organisations—must make their expertise available for the service and welfare of their communities. International agencies and governments must also take decisive action, deploying the appropriate resources to contain the epidemic.

Development of a scale to measure individuals’ ratings of peace

Conflict and Health
[Accessed 27 September 2014]
http://www.conflictandhealth.com/

Research
Development of a scale to measure individuals’ ratings of peace
Howard Zucker, Roy Ahn, Samuel Justin Sinclair, Mark Blais, Brett D Nelson and Thomas F Burke
Author Affiliations
Conflict and Health 2014, 8:17 doi:10.1186/1752-1505-8-17
Published: 27 September 2014
Abstract (provisional)
Background
The evolving concept of peace-building and the interplay between peace and health is examined in many venues, including at the World Health Assembly. However, without a metric to determine effectiveness of intervention programs all efforts are prone to subjective assessment. This paper develops a psychometric index that lays the foundation for measuring community peace stemming from intervention programs.
Methods
After developing a working definition of ‘peace’ and delineating a Peace Evaluation Across Cultures and Environments (PEACE) scale with seven constructs comprised of 71 items, a beta version of the index was pilot-tested. Two hundred and fifty subjects in three sites in the U.S. were studied using a five-point Likert scale to evaluate the psychometric functioning of the PEACE scale. Known groups validation was performed using the SOS-10. In addition, test-retest reliability was performed on 20 subjects.
Results
The preliminary data demonstrated that the scale has acceptable psychometric properties for measuring an individual’s level of peacefulness. The study also provides reliability and validity data for the scale. The data demonstrated internal consistency, correlation between data and psychological well-being, and test-retest reliability.
Conclusions
The PEACE scale may serve as a novel assessment tool in the health sector and be valuable in monitoring and evaluating the peace-building impact of health initiatives in conflict-affected regions.

Globalization and Health [Accessed 27 September 2014]

Globalization and Health
[Accessed 27 September 2014]
http://www.globalizationandhealth.com/

Commentary
A call for a moratorium on the .health generic top-level domain: preventing the commercialization and exclusive control of online health information
Mackey TK, Eysenbach G, Liang BA, Kohler JC, Geissbuhler A and Attaran A Globalization and Health 2014, 10:62 (26 September 2014)
Abstract
In just a few weeks, the Internet could be expanded to include a new .health generic top-level domain name run by a for-profit company with virtually no public health credentials – unless the international community intervenes immediately. This matters to the future of global public health as the “Health Internet” has begun to emerge as the predominant source of health information for consumers and patients. Despite this increasing use and reliance on online health information that may have inadequate quality or reliability, the Internet Corporation for Assigned Names and Numbers (ICANN) recently announced it intends to move forward with an auction to award the exclusive, 10 year rights to the .health generic top-level domain name. This decision is being made over the protests of the World Medical Association, World Health Organization, and other stakeholders, who have called for a suspension or delay until key questions can be resolved. However, rather than engage in constructive dialogue with the public health community over its concerns, ICANN chose the International Chamber of Commerce—a business lobbying group for industries to adjudicate the .health concerns. This has resulted in a rejection of challenges filed by ICANN’s own independent watchdog and others, such that ICANN’s Board decided in June 2014 that there are “no noted objections to move forward” in auctioning the .health generic top-level domain name to the highest bidder before the end of the year. This follows ICANN’s award of several other health-related generic top-level domain names that have been unsuccessfully contested. In response, we call for an immediate moratorium/suspension of the ICANN award/auction process in order to provide the international public health community time to ensure the proper management and governance of health information online.

Debate
On the margins of aid orthodoxy: the Brazil-Mozambique collaboration to produce essential medicines in Africa
Russo G, de Oliveira L, Shankland A and Sitoe T Globalization and Health 2014, 10:70 (25 September 2014)
Abstract (provisional)
Background
On the back of its recent economic development and domestic success in the fight against HIV/AIDS, Brazil is helping the Government of Mozambique to set up a pharmaceutical factory as part of its South-South cooperation programme. Until recently, a consensus existed that pharmaceutical production in Africa was not viable or sustainable. This paper looks into practicalities and evolution of this collaboration to illustrate the characteristics of Brazilian development cooperation in health, with the aim of drawing lessons for the wider debate on aid and local production of pharmaceuticals in Africa.
Discussion
We show that the project process has been very long and complex, has involved multiple public and private partners, and cost in excess of USD34 million. There have also been setbacks in the process, and although production has already started, it is unclear whether all the project’s original objectives will be met.
Summary
The Brazil-Mozambique’s pharmaceutical factory experience illustrates positives as well as limitations of Brazil’s unorthodox approach to health development cooperation, highlighting its contribution to pushing the boundaries of the debate on local production of pharmaceuticals in resource-poor settings.

Transnationalism and Ethnic Identification among Adolescent Children of Immigrants in the Netherlands, Germany, England, and Sweden

International Migration Review
Fall 2014 Volume 48, Issue 3 Pages 577–917
http://onlinelibrary.wiley.com/doi/10.1111/imre.2014.48.issue-2/issuetoc

SPECIAL SECTION OF IMMIGRATION POLICY IN AUSTRALIA, CANADA, NEW ZEALAND AND THE UNITED STATES

Original Article
Transnationalism and Ethnic Identification among Adolescent Children of Immigrants in the Netherlands, Germany, England, and Sweden
Paulien Schimmer1 and Frank van Tubergen2
Article first published online: 9 APR 2014
DOI: 10.1111/imre.12084
Abstract
Inspired by the emerging literature on transnationalism in the United States, this paper studies the return visits of adolescent children of immigrants in four European countries. Using data from the Children of Immigrants Longitudinal Study, cross-classified multilevel analyses indicate that parental economic resources, ethnic motivations, and political suppression are related to adolescent children of immigrants’ return visits. Furthermore, return visits are positively related to adolescents’ identification with the origin country and negatively to adolescents’ identification with the host country.

Four centuries on from Bacon: progress in building health research systems to improve health systems?

Health Research Policy and Systems
http://www.health-policy-systems.com/content
[Accessed 27 September 2014]

Editorial
Four centuries on from Bacon: progress in building health research systems to improve health systems?
Stephen R Hanney1* and Miguel A González-Block2
* Corresponding author: Stephen R Hanney
Author Affiliations
Health Research Policy and Systems 2014, 12:56 doi:10.1186/1478-4505-12-56
Published: 23 September 2014
Abstract
In 1627, Francis Bacon’s New Atlantis described a utopian society in which an embryonic research system contributed to meeting the needs of the society. In this editorial, we use some of the aspirations described in New Atlantis to provide a context within which to consider recent progress in building health research systems to improve health systems and population health. In particular, we reflect on efforts to build research capacity, link research to policy, identify the wider impacts made by the science, and generally build fully functioning research systems to address the needs identified.

In 2014, Health Research Policy and Systems has continued to publish one-off papers and article collections covering a range of these issues in both high income countries and low- and middle-income countries. Analysis of these contributions, in the context of some earlier ones, is brought together to identify achievements, challenges and possible ways forward. We show how 2014 is likely to be a pivotal year in the development of ways to assess the impact of health research on policies, practice, health systems, population health, and economic benefits.

We demonstrate how the increasing focus on health research systems will contribute to realising the hopes expressed in the World Health Report, 2013, namely that all nations would take a systematic approach to evaluating the outputs and applications resulting from their research investment.

Journal of Community Health – October 2014 [HPV analysis]

Journal of Community Health
Volume 39, Issue 5, October 2014
http://link.springer.com/journal/10900/39/4/page/1

Original Paper
Views on Human Papillomavirus Vaccination: A Mixed-Methods Study of Urban Youth
Melissa K. Miller, Joi Wickliffe, Sara Jahnke…

Original Paper
Parents’ Decisions About HPV Vaccine for Sons: The Importance of Protecting Sons’ Future Female Partners
Christine L. Schuler, Nancy S. DeSousa, Tamera Coyne-Beasley

Original Paper
Understanding HPV Vaccine Uptake Among Cambodian American Girls
Victoria M. Taylor, Nancy J. Burke, Linda K. Ko…

The Lancet – Sep 27, 2014

The Lancet
Sep 27, 2014 Volume 384 Number 9949 p1159 – 1236
http://www.thelancet.com/journals/lancet/issue/current

Editorials
Women, children, and adolescents: the post-2015 agenda
The Lancet
Preview |
As the global health community and government representatives gathered in New York this week to review progress towards the Millennium Development Goals (MDGs) and considered their successors the Sustainable Development Goals (SDGs), there is some good news to share and some not so good. Child mortality in under-5-year-olds worldwide has fallen from 12•7 million in 1990 to 6•3 million in 2013. Although the present rate of decrease is still not enough to meet MDG 4 (a reduction of under-5 child mortality by two thirds by the end of 2015), it is still remarkable progress.

Reducing the number of disaster refugees
The Lancet
Preview |
Natural disasters are inevitable but are the population displacements they cause also unavoidable? 22 million people were made refugees by natural disasters in 2013, according to a report released last week from the Internal Displacement Monitoring Centre and the Norwegian Refugee Council. This number is three-times higher than that for displacements caused by conflicts in 2013.

Series
Midwifery
Country experience with strengthening of health systems and deployment of midwives in countries with high maternal mortality
Wim Van Lerberghe, Zoe Matthews, Endang Achadi, Chiara Ancona, James Campbell, Amos Channon, Luc de Bernis, Vincent De Brouwere, Vincent Fauveau, Helga Fogstad, Marge Koblinsky, Jerker Liljestrand, Abdelhay Mechbal, Susan F Murray, Tung Rathavay, Helen Rehr, Fabienne Richard, Petra ten Hoope-Bender, Sabera Turkman

Improvement of maternal and newborn health through midwifery
Petra ten Hoope-Bender, Luc de Bernis, James Campbell, Soo Downe, Vincent Fauveau, Helga Fogstad, Caroline S E Homer, Holly Powell Kennedy, Zoe Matthews, Alison McFadden, Mary J Renfrew, Wim Van Lerberghe

The Lancet Global Health – Oct 2014 :: Ebola analysis

The Lancet Global Health
Oct 2014 Volume 2 Number 10 e550 – 615
http://www.thelancet.com/journals/langlo/issue/current

Ebola: the missing link
Zoë Mullan a
“Liberia is facing a serious threat to its national existence.” So said the country’s Defence Minister, Brownie Samukai, earlier this month. For a nation that has only just seen the UN Refugee Agency withdraw after a 14-year civil war in which a quarter of a million people perished, Samukai’s words are chilling. Ebola virus entered the country from Guinea in the early part of 2014, and has since killed at least half of the 2218 people reported to have died in the west African outbreak as of Sept 7. After doing little more than spectate for almost 6 months, the world has now risen from the bleachers and set about some action.

The inadequacy of the international community’s initial response to this unusually fast-spreading urban outbreak has been lamented at length, as have WHO’s weakened capacity in the face of budget and staff cuts, and the lack of an emergency response fund and centralised global command and control structure to enable swift deployment of resources and trained personnel. However, at least we have now caught up with what is actually happening and have begun to monitor it. WHO’s regular situation reports have become a must-read and the agency’s prediction of an exponential increase in the number of new cases of Ebola virus disease in Liberia is proving tragically accurate. WHO’s Ebola Response Roadmap is a useful document and is hard to fault for its practical advice. Donor commitments are starting to arrive. But will data, directions, and donations be enough?

Respected voices such as those of Médecins Sans Frontières (MSF) and Ebolavirus co-discoverer Peter Piot have called for a military response to the coordination of supplies and the building of health centres, for UN peacekeeping forces to be deployed, and for individual Western governments to encourage and enable health workers to offer their assistance on the ground. In the case of Liberia, WHO has warned of the need for “non-conventional interventions”, whatever they may be. Amid scenes of men, women, and children prostrate outside treatment centres with no beds; of the exhaustion of national and international health workers alike; and in the face of what seems to be the infuriatingly ponderous nature of global health institutions, it is hard not to issue an empassioned plea for someone, somewhere to “do something”.

However, provision of military assistance or even well trained Western medical staff is not a panacea. The imagery conjured up by foreigners in biohazard suits or army camouflage can be powerfully negative, and even associated with the bringing of disease, rather than its banishment, as happened with cholera in Haiti. What is also vital in west Africa right now is the interface between the essential efforts of the international community and the needs of the populations affected: the entity that converts funds into care, information into understanding, and precautions into safety. In other words, the national governments of Liberia, Sierra Leone, and Guinea.

Some of the governments’ responses to the current crisis have been badly misjudged. Most notably, Liberia’s efforts to quarantine an affected community in West Point township in the capital Monrovia had disastrous consequences, with a heavy-handed security presence leading to the fatal shooting of a 15-year-old boy. Sierra Leone has threatened a 2-year gaol term on anyone found to be hiding a patient with Ebola virus disease. And, back in Liberia, President Ellen Johnson-Sirleaf’s declared 90-day state of emergency included “the suspensions of certain rights and privileges”, without stating what these were. None of these actions engenders the trust that is so crucial to the containment of the epidemic. Without trust, families will continue to hide sick loved ones, and health workers and mortuary staff will continue to be attacked.

Liberia, Sierra Leone, and Guinea are some of the poorest nations in the world, and two are still in the early stages of recovery from a devastating conflict. The international community must therefore do everything possible to assist with resources, staff, and logistics in the face of this humanitarian catastrophe. But what must not be forgotten is the responsibility of the national authorities to direct and communicate in a way that protects the human rights of those they have been elected to lead. The people of Liberia, and those of other affected countries, must be able to rely on the commitment, transparency, and cohesion of their own governments in times of national crisis.
Rethinking the development of Ebola treatments
Rajesh Gupta a
In response to the current outbreak, the international community has endorsed the clinical use of unregistered treatments for Ebola.1 Even with this accelerated pathway to in-human testing and use, radically novel approaches to drug development will be needed to improve the likelihood that a treatment is realised. Bypassing steps in development does not alter the probability of success, and historical patterns in drug development suggest that there is a slim probability of success with the current portfolio of potential Ebola treatments (all of which are were in preclinical development prior to the outbreak).

First, preclinical research in drug development can suffer from a lack of replicability, which contributes to high development failure rates.2 Second, if preclinical development is successful, the likelihood of successful regulatory approval of all investigational drugs reaching phase 1 is only 10•4%.3 Third, these patterns and low rates are based on therapeutic areas with: (a) robust preclinical and clinical data collected (often) over decades from hundreds to thousands of research and development activities spanning the globe, and (b) socially and politically acceptable clinical development programmes spanning large populations, mainly in resource-wealthy settings with strong clinical trial infrastructure. Ebola stands in stark contrast to such therapeutic areas; thus, one could expect that the likelihood of successful regulatory approval for an Ebola treatment would be lower than these estimates.

Repurposing (use of approved drugs for new indications) or repositioning (use of drugs whose development was not continued for new indications) of existing drugs has been put forward as a method to overcome some of these issues.4 Indeed, drug repositioning and repurposing could lead to higher rates of success, with lower costs of development, in a faster timeframe than de novo discovery approaches.5 However, these potential advantages are far from certain. Furthermore, drug repurposing/repositioning in and of itself does not remove the need for certain preclinical studies and clinical trials. Drugs still need to be validated and studied in the indications for which they are proposed.

In silico approaches might hold a key to overcoming some of these obstacles. Use of bioinformatics-based high-end computing to simulate drug—disease biological processes provides the ability to bypass time-consuming and costly in vitro and in vivo studies and increase the probability of success of clinical trials.6 For Ebola treatments, in silico approaches might offer two specific means to improve the current process and help address some of the critical preclinical and clinical concerns raised at the WHO meeting of international experts to discuss Ebola therapeutics on Sept 5.7 First, the number of preclinical compounds already containing clinical data for other therapeutic indications could be considerably increased. Although traditional repositioning methods using in vitro screening have led to initial discoveries for Ebola,8 computational screening could provide the needed efficiency to identify candidates more rapidly and accurately than de novo discovery methods. Second, virtual clinical trials could alleviate some of the logistical and ethical issues surrounding the clinical use of unregistered Ebola treatments, including the balance between generating safety data and the need to introduce treatments as soon as possible.9 This method would permit non-interventional assessments of pharmacokinetic-pharmacodynamic parameters and allow precise and efficient clinical trial design10 (the latter being particularly important because the epidemiology and infrequent emergence of Ebola often provides a narrow window of opportunity and limited population size to assess an intervention). There is at least one caveat, though. In silico approaches are dependent on drug and disease process data. Therapeutic Ebola research is heavily funded by the US government under the auspices of threats to national security,11 and international activities are limited to a few research groups. To allow for greater participation of researchers globally, real-time accessibility of crucial data is necessary.7

In silico methods are still in development and rapidly evolving, but have been successful in identifying potential candidates for various diseases and the risk of using such methods are very low. Their ability to affect, at scale, drug development processes, costs, and timelines is unknown but likely to be considerable given the private sector’s strong interest and investment in this area. Equally likely is that these approaches will be able to affect a wide range of diseases. Although these approaches are currently directed towards diseases with clear revenue streams (eg, inflammatory bowel disease and cancer), such approaches could be used for unprofitable diseases that affect the most underserved populations of the world.

The inequities already posed by a disease of poverty such as Ebola become further exacerbated when novel technologies are used first to explore diseases that are viable commercial opportunities. This does not have to be the pattern moving forward, and Ebola might provide the opportunity to apply new technological approaches to drug development (such as in silico methods) for traditional “market failure” diseases. If the global community is truly committed to rapidly developing a new drug for Ebola, multiple novel approaches, methods, and technologies will need to be used to beat the inherent hurdles of drug development.

1 Enserink M. Debate erupts on repurposed drugs for Ebola. Science 2014; 345: 718-719. PubMed
2 Begley C, Ellis LM. Drug development: raise standards for preclinical cancer research. Nature 2012; 483: 531-533. PubMed
3 Hay M, Thomas DW, Craighead JL, Economidies C, Rosenthal J. Clinical development success rates for investigational drugs. Nature Biotechnol 2014; 32: 40-51. PubMed
4 Editorial. New approaches for Ebola therapeutics. New York Times Aug 24, 2014.
5 Institute of Medicine. Drug repurposing and repositioning: workshop summary. Washington, DC: National Academies Press, 2014. http://www.iom.edu/Reports/2014/Drug-Repurposing-and-Repositioning.aspx. (accessed Sept 5, 2014).
6 Dudley JT, Deshpande T, Butte A. Exploiting drug-disease relationships for computational drug repositioning. Brief Bioinform 2011; 12: 303-311. PubMed
7 WHO. Statement on the WHO Consultation on potential Ebola therapies and vaccines. http://www.who.int/mediacentre/news/statements/2014/ebola-therapies-consultation/en/. (accessed Sept 8, 2014).
8 Johansen LM, Brannan JM, Delos SE, et al. FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection. Sci Transl Med 2013; 190: 90ra79. PubMed
9 Arie S. Ebola: an opportunity for a clinical trial?. BMJ 2014; 349: g4997. PubMed
10 Holford N, Ma SC, Ploeger BA. Clinical trial simulation: a review. Clin Pharmacol Ther 2010; 88: 166-168. PubMed
11 Enserink M. Ebola drugs still stuck in lab. Science 2014; 345: 364-365. PubMed

The Lancet Infectious Diseases – Oct 2014

he Lancet Infectious Diseases
Oct 2014 Volume 14 Number 10 p899 – 1022
http://www.thelancet.com/journals/laninf/issue/current

Treatment outcomes of childhood tuberculous meningitis: a systematic review and meta-analysis
Silvia S Chiang, Faiz Ahmad Khan, Meredith B Milstein, Arielle W Tolman, Andrea Benedetti, Jeffrey R Starke, Mercedes C Becerra
Preview |
Despite treatment, childhood tuberculous meningitis has very poor outcomes. Poor prognosis and difficult early diagnosis emphasise the importance of preventive therapy for child contacts of patients with tuberculosis and low threshold for empirical treatment of tuberculous meningitis suspects. Implementation of consensus definitions, standardised reporting of data, and high-quality clinical trials are needed to clarify optimum therapy.

Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study
A/Prof Sepehr N Tabrizi PhD a b c d, Julia M L Brotherton BMed e f, Prof John M Kaldor PhD g, S Rachel Skinner PhD f, Bette Liu DPhil h, Deborah Bateson MBBS i, Kathleen McNamee MBBS j k, Maria Garefalakis MBBS l, Samuel Phillips BSc a d, Eleanor Cummins BSc a d, Michael Malloy PhD e, Prof Suzanne M Garland MD a b c d
Summary
Background
After the introduction of a quadrivalent human papillomavirus (HPV) vaccination programme in Australia in April, 2007, we measured the prevalence of vaccine-targeted and closely related HPV types with the aim of assessing direct protection, cross-protection, and herd immunity.
Methods
In this repeat cross-sectional study, we recruited women aged 18—24 years who attended Pap screening between October, 2005, and July, 2007, in three major metropolitan areas of Australia to form our prevaccine-implementation sample. For our postvaccine-implementation sample, we recruited women aged 18—24 years who attended Pap screening in the same three metropolitan areas from August, 2010, to November, 2012. We compared the crude prevalence of HPV genotypes in cervical specimens between the prevaccine and the postvaccine implementation groups, with vaccination status validated against the National HPV Vaccination Program Register. We estimated adjusted prevalence ratios using log linear regression. We estimated vaccine effectiveness both for vaccine-targeted HPV types (16, 18, 6, and 11) and non-vaccine but related HPV types (31, 33, and 45).
Findings
202 women were recruited into the prevaccine-implementation group, and 1058 were recruited into the postvaccine-implementation group. Crude prevalence of vaccine-targeted HPV genotypes was significantly lower in the postvaccine-implementation sample than in the prevaccine-implementation sample (58 [29%] of 202 vs 69 [7%] of 1058; p<0•0001). Compared with the prevaccine-implementation sample, adjusted prevalence ratios for vaccine-targeted HPV genotypes were 0•07 (95% CI 0•04—0•14; p<0•0001) in fully vaccinated women and 0•65 (0•43—0•96; p=0•03) in unvaccinated women, which suggests herd immunity. No significant declines were noted for non-vaccine-targeted HPV genotypes. However, within the postvaccine-implementation sample, adjusted vaccine effectiveness against vaccine-targeted HPV types for fully vaccinated women compared with unvaccinated women was 86% (95% CI 71—93), and was 58% (26—76) against non-vaccine-targeted but related genotypes (HPV 31, 33, and 45).
Interpretation
6 years after the initiation of the Australian HPV vaccination programme, we have detected a substantial fall in vaccine-targeted HPV genotypes in vaccinated women; a lower prevalence of vaccine-targeted types in unvaccinated women, suggesting herd immunity; and a possible indication of cross-protection against HPV types related to the vaccine-targeted types in vaccinated women.
Funding
Australian National Health and Medical Research Council and Cancer Council Victoria.

Series
Emerging respiratory tract infections
Surveillance for emerging respiratory viruses
Jaffar A Al-Tawfiq, Alimuddin Zumla, Philippe Gautret, Gregory C Gray, David S Hui, Abdullah A Al-Rabeeah, Ziad A Memish
Summary
Several new viral respiratory tract infectious diseases with epidemic potential that threaten global health security have emerged in the past 15 years. In 2003, WHO issued a worldwide alert for an unknown emerging illness, later named severe acute respiratory syndrome (SARS). The disease caused by a novel coronavirus (SARS-CoV) rapidly spread worldwide, causing more than 8000 cases and 800 deaths in more than 30 countries with a substantial economic impact. Since then, we have witnessed the emergence of several other viral respiratory pathogens including influenza viruses (avian influenza H5N1, H7N9, and H10N8; variant influenza A H3N2 virus), human adenovirus-14, and Middle East respiratory syndrome coronavirus (MERS-CoV).

Emerging respiratory tract infections
Emerging infectious diseases and pandemic potential: status quo and reducing risk of global spread
Brian McCloskey, Osman Dar, Alimuddin Zumla, David L Heymann
Preview |
Emerging infectious diseases are an important public health threat and infections with pandemic potential are a major global risk. Although much has been learned from previous events the evidence for mitigating actions is not definitive and pandemic preparedness remains a political and scientific challenge. A need exists to develop trust and effective meaningful collaboration between countries to help with rapid detection of potential pandemic infections and initiate public health actions. This collaboration should be within the framework of the International Health Regulations.